The Healthcare Data

Emmaus Life Sciences Reports Annual Financial Results

Emmaus

Emmaus Life Sciences Announces Full-Year 2025 Financial Results Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company focused on treatments for sickle cell disease, has reported its financial condition and operating results for the year ended December 31, 2025. The company’s…

CADENCE Phase 2 Data Support WINREVAIR™ in CpcPH-HFpEF

CADENCE

Merck Reports Positive Phase 2 CADENCE Results for WINREVAIR in CpcPH-HFpEF, Supporting Advancement to Phase 3 Merck has announced encouraging results from its Phase 2 CADENCE clinical trial evaluating WINREVAIR™ (sotatercept-csrk) in adults diagnosed with combined post- and precapillary pulmonary…